These results hold promise that a non-invasive prostate cancer screening test yielding both high sensitivity and specificity may soon make its way into health care practices.
Going forward, the team hopes to fund a full clinical trial and work with industry partners to develop the Odoreader into a scalable format. And while the focus of the pilot study was on prostate cancer, Probert said that in upcoming bladder cancer work, they will be studying the Odoreader as a screening tool for women, as well. In the longer term, they also intend to trial the Odoreader as a diagnostic tool for other forms of urologic cancers, such as testicular and kidney cancer.
Ad Statistics
Times Displayed: 31012
Times Visited: 807 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
The research team is concurrently studying the efficacy of this diagnostic method on Probert’s primary research interest, inflammatory bowel disease. In a statement, he said the group is planning to publish those findings in the near future.
Back to HCB News
